Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1401 to 1450 of 2053 results for work

  1. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC

  2. Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer [ID1135]

    Discontinued Reference number: GID-TA10233

  3. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued Reference number: GID-TAG424

  4. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

  5. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued Reference number: GID-TAG433

  6. Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]

    In development Reference number: GID-TA10882 Expected publication date: TBC

  7. Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]

    In development Reference number: GID-TA10758 Expected publication date: TBC

  8. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

  9. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    In development Reference number: GID-TA11044 Expected publication date: TBC

  10. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    In development Reference number: GID-TA11093 Expected publication date: TBC

  11. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development Reference number: GID-TA11166 Expected publication date: TBC

  12. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued Reference number: GID-TAG369

  13. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued Reference number: GID-TA10033

  14. Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]

    In development Reference number: GID-TA10822 Expected publication date: TBC

  15. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development Reference number: GID-TA11569 Expected publication date: TBC

  16. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    In development Reference number: GID-TA11074 Expected publication date: TBC

  17. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

  18. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

  19. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

  20. Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]

    Discontinued Reference number: GID-TA11109

  21. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

  22. AI technologies for detecting diabetic retinopathy (MIB265)

    NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .

  23. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

  24. Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

    Discontinued Reference number: GID-TA10416

  25. Benralizumab for previously treated severe nasal polyps [ID1659]

    In development Reference number: GID-TA10818 Expected publication date: TBC

  26. Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629

    Discontinued Reference number: GID-TA10841

  27. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development Reference number: GID-TA11146 Expected publication date: TBC

  28. VTS-270 for treating Niemann-Pick type C1 [ID1267]

    In development Reference number: GID-HST10020 Expected publication date: TBC

  29. StoneChecker for kidney stone evaluation (MIB171)

    NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .

  30. Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

    Discontinued Reference number: GID-TA10527

  31. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued Reference number: GID-TA10151

  32. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

  33. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

  34. Acne vulgaris: management (NG198)

    This guideline covers management of acne vulgaris in primary and specialist care. It includes advice on topical and oral treatments (including antibiotics and retinoids), treatment using physical modalities, and the impact of acne vulgaris on mental health and wellbeing.

  35. Type 1 diabetes in adults: diagnosis and management (NG17)

    This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.

  36. Path Finder for freezing of gait in people with Parkinson's disease (MIB170)

    NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .

  37. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development Reference number: GID-TA10696 Expected publication date: TBC

  38. Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033]

    Discontinued Reference number: GID-TA10081

  39. Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]

    Discontinued Reference number: GID-TA10088

  40. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

  41. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued Reference number: GID-TAG409

  42. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

  43. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued Reference number: GID-TA10202

  44. SecurAcath for securing percutaneous catheters (HTG440)

    Evidence-based recommendations on SecurAcath for securing percutaneous catheters.

  45. One-piece closed bags for colostomies: late-stage assessment (HTG754)

    Late stage assessment (LSA) guidance on one-piece closed bags for colostomies

  46. Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

    In development Reference number: GID-TA10747 Expected publication date: TBC

  47. Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin's lymphoma [ID1044]

    Discontinued Reference number: GID-TA10087

  48. Surgical site infection (QS49)

    This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.

  49. Alcohol-use disorders: diagnosis and management (QS11)

    This quality standard covers identifying and supporting adults and young people (aged 10 and over) who may have an alcohol-use disorder and caring for people with alcohol-related health problems, as well as support for their families and carers. It describes high-quality care in priority areas for improvement.

  50. Faecal incontinence in adults (QS54)

    This quality standard covers managing faecal (bowel) incontinence in adults (aged 18 and over) in the community (at home and in care homes) and in all hospital departments. It includes assessment of bowel control problems, advice and support, and treatment options. It describes high-quality care in priority areas for improvement.